IncellDx Inks Chinese Distribution Deal With GIMDx

Oct 19, 2017

NEW YORK (GenomeWeb) – GIMDx announced today that it has signed an exclusive distribution agreement for IncellDx's single-cell immune-oncology and oncology diagnostic products in China.

Under the terms of the agreement, GIMDx will supply its China-based parent company Guangzhou Improve Medical Instruments with IncellDx component products, which will be kitted and co-labeled for the Chinese in vitro diagnostic market.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Apr

23

Featured Webinar

AMP/ACMG/CAP Cancer Sequence Variant Guidelines: A Two-Year Status Report

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence.

Apr

24

Featured Webinar

Metabolomics Analyses to Elucidate Systemic Processes in Human Health and Disease

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu